アフターアワーズ： 3.80

Prime Medicine Inc (PRME)

Prime Medicine Inc (PRME) 最新ニュース

Prime Medicine Inc (PRME)

Prime Medicine Inc (PRME) 最新ニュース

Why I Keep Buying These 14 Incredible Growth Stocks - The Motley Fool

There is no doubt that Prime Medicine Inc (PRME) ticks all the boxes. - SETE News

Prime Medicine to Highlight New Preclinical Data, Including - GlobeNewswire

Market Watch Highlights: Prime Medicine Inc (PRME) Ends on an Upturn Note at 3.73 - The Dwinnex

Prime Medicine Inc (PRME) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News

Millennium Management LLC Has $6.84 Million Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat

The Significance of Moving Averages in Prime Medicine Inc Inc. (PRME) Price Performance - The InvestChronicle

Check out these key findings about Prime Medicine Inc (PRME) - SETE News

Prime Medicine Inc [PRME] Investment Guide: What You Need to Know - Knox Daily

Insider’s View: Deciphering Prime Medicine Inc (PRME)’s Financial Health Through Ratios - The Dwinnex

Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday - MSN

A new trading data show Prime Medicine Inc (PRME) is showing positive returns. - SETE News

Prime Medicine Inc (PRME) rating initates by H.C. Wainwright - Knox Daily

Prime Medicine, Inc. Expected to Earn Q4 2024 Earnings of ($0.28) Per Share (NYSE:PRME) - Defense World

Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Prime Medicine’s (PRME) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Q4 2024 EPS Estimates for Prime Medicine, Inc. (NYSE:PRME) Lifted by Wedbush - MarketBeat

PRME Stock Rises 11.8% on Collaboration With Bristol Myers - Zacks Investment Research

BMS Inserts Cash Into Prime Medicine’s Gene-Editing Ambitions - Scrip

BMS and Prime ink potential $3.5bn deal to develop T cell therapies - Yahoo Finance

Prime Medicine outlines plans for gene editing pipeline - BioWorld Online

BMO maintains Outperform rating on Prime Medicine after BMS partnership By Investing.com - Investing.com UK

Juno Therapeutics, Inc. entered into research and collaboration agreement to acquire An exclusive worldwide license to certain Prime Editing technology from Prime Medicine, Inc. for approximately $3.6 billion. - Marketscreener.com

Prime Medicine, Bristol Myers Squibb ink gene editing deal By Investing.com - Investing.com South Africa

Prime Medicine, Bristol Myers Squibb ink gene editing deal - Investing.com

Prime Medicine shares hold Buy rating amid BMS deal By Investing.com - Investing.com Canada

Citi maintains Buy on Prime Medicine, price target at $10 By Investing.com - Investing.com Canada

Citi maintains Buy on Prime Medicine, price target at $10 - Investing.com

Prime Medicine focuses on key genetic therapy programs - Investing.com

Prime Medicine shares rise on $3.5 billion BMS collaboration By Investing.com - Investing.com Canada

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday - MSN

Prime Medicine's SWOT analysis: gene editing firm's stock potential - Investing.com India

Prime Medicine, Inc. (NYSE:PRME) Shares Sold by Ensign Peak Advisors Inc - Defense World

Prime’s $3.61B Bristol Myers deal is year’s fourth largest - BioWorld Online

Charting the Course: Prime Medicine Inc’s PRME Stock Prospects - The InvestChronicle

Prime Medicine shares rise on $3.5 billion BMS collaboration - Investing.com

Prime Medicine shares hold Buy rating amid BMS deal - Investing.com India

Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace

Prime Medicine (PRME) Stock Jumps On Collaboration News - Stocks Telegraph

Prime Medicine (NYSE:PRME) Shares Gap Up to $3.46 - Defense World

Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb - MedCity News

Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates - MSN

Prime Medicine soars as it inks research collab with BMS - The Pharma Letter

Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates (NASDAQ:PRME) - Seeking Alpha

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher - Benzinga

Bristol, Prime Medicine in deal to develop T-cell therapies - Seeking Alpha

Financial Health Check: Examining Prime Medicine Inc (PRME)’s Key Ratios - The Dwinnex

Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline - Genetic Engineering & Biotechnology News

Prime Medicine Inc (PRME) did well last session? - US Post News

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - AOL

Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley - TipRanks

Prime Medicine pact with Bristol doesn’t change thesis, says Stifel - TipRanks

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb - Morningstar

A radiopharmaceuticals startup raises $175 million - STAT

Prime Medicine focuses on key genetic therapy programs By Investing.com - Investing.com Canada

Prime Medicine Strikes $3.5B Deal for T-Cell Therapy Advances - TipRanks

Prime Medicine rises after investment from Bristol Myers, licensing deal - XM

Prime Medicine unveils strategically focused pipeline - TipRanks

Prime Medicine Unveils Strategically Focused Pipeline - GlobeNewswire

Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb - STAT

PRMEに似た銘柄